Weight-loss drugs slow biological aging by 2-3 years

novo nordisk and eli lilly conducted studies on their glp-1 weight-loss drugs, finding that they reduce molecular markers of age in patients. the drugs, including semaglutide, resulted in a 2-3 year slowdown in biological aging. this was measured using molecular 'aging clocks' that assess dna changes and protein levels. the studies involved large patient groups, such as novo's 10,052 participants. the findings suggest that glp-1 drugs may act on basic causes of aging and could be a true longevity treatment. this affects overweight and diabetic patients, potentially changing the approach to aging and healthspan.